Takeda Pharmaceuticals and Affymax, Inc. (AFFY) Announce Supply Agreement for OMONTYS┬«(peginesatide) Injection With Renal Care Group, Inc. (RCGI)  
8/9/2012 10:22:46 AM

DEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A. (TPUSA) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS®(peginesatide) Injection with U.S. Renal Care, Inc. and certain of its affiliates, representing one of the top 10 dialysis providers in the United States (U.S.). OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population with chronic kidney disease (CKD) in the U.S.